

BEST AVAILABLE COPY

1651



Attorney Docket No. PP01639.102 (CHIR-1639/00US)

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on 4/8/03.

By: 

Yang Tang

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of MASIGNANI et al.

Serial No.: 10/031,289

Examiner: unassigned

Confirmation No.: 6882

Art Unit: 1651

Filing Date: May 31, 2002

For: ANTIGENIC MENINGOCOCCAL PEPTIDES

TECH CENTER 1600/2900

APR 16 2003

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

- ☒ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ In accordance with 37 C.F.R. §1.97(c), also enclosed is:
- ☐ the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
- ☐ a statement as specified in 37 C.F.R. §1.97(e).
- ☐ In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ Check No. \_\_\_ in the amount of \$\_\_\_ for the total fee is attached.
- ☒ A return receipt postcard is also enclosed.

☐ Please charge \$\_\_ to Deposit Account No. 03-3117 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Please direct all further written communications in this application to:


Alisa A. Harbin, Esq.  
Chiron Corporation  
Intellectual Property – R440  
P.O. Box 8097  
Emeryville, CA 94662-8097

Dated: 4/8/03

Respectfully submitted,  
**COOLEY GODWARD LLP**


Chiron Corporation  
Intellectual Property – R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Tel: (650) 843-5000  
Fax: (650) 857-0663

By:

  
Roberta L. Robins  
Reg. No. 33,208



Please type a plus sign (+) inside this box →



**BEST AVAILABLE COPY**

PTO/SB/08A (08-00)

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/031,289	
			Filing Date	May 31, 2002	
			First Named Inventor	MASIGNANI	
			Group Art Unit	1651	
			Examiner Name	unassigned	
Sheet	2	of	2	Attorney Docket Number	PP01639.102 (CHIR-1639/00US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	ALA'ALDEEN et al. (1996) "The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains," <i>Vaccine</i> , 14(1): 49-53	
	C2	BIEGEL CARSON et al. (1999) "Ferric enterobactin binding and utilization by Neisseria gonorrhoeae", <i>Journal of Bacteriology</i> , 181(9): 2895-2901	
	C3	CHRISTODOULIDES et al. (1994) "Immunization with a multiple antigen peptide containing defined B- and T-cell epitopes: production of bactericidal antibodies against group B Neisseria meningitidis", <i>Microbiology</i> , 140(11): 2951-2960	
	C4	DELVIG et al. (1996) "Immune responses to linear epitopes on the porB protein of Neisseria meningitidis in patients with systemic meningococcal disease", <i>Microbiology</i> , 142(9): 2491-2498	
	C5	POOLMAN et al. (1995) "Development of a Meningococcal Vaccine," <i>Infect. Agents and Dis.</i> , 4: 13-28	
	C6	ROKBI et al. (1995) "Variable sequences in a mosaic-like domain of meningococcal tbp2 encode immunoreactive epitopes", <i>FEMS Microbiology Letters</i> , 132: 277-283	

**RECEIVED**  
 APR 16 2003  
 TECH CENTER 1600/2900

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> Applicant is to place a check mark here if English language Translation attached.